Home > Insider Trading > Filing (0001127602-11-028572)

Filing Details

Accession Number:: 0001127602-11-028572
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-11-03 16:17:38
Reporting Period:: 2011-11-01

Filing Date:: 2011-11-03
Accepted Time:: 2011-11-03 16:17:38
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1022079	Quest Diagnostics Inc	DGX	Services-Medical Laboratories (8071)	161387862

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1222676	Robert Hagemann	C/O Quest Diagnostics Incorporated 3 Giralda Farms Madison NJ 07940	Svp & Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-11-01	1,650	$35.53	141,313	No	4	M	Direct
Common Stock	Disposition	2011-11-01	1,650	$54.85	139,663	No	4	S	Direct
Common Stock	Acquisiton	2011-11-01	2,500	$48.74	142,163	No	4	M	Direct
Common Stock	Disposition	2011-11-01	2,500	$54.77	139,675	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options (Right to Buy)	Disposition	2011-11-01	1,650	$0.00	1,650	$35.53
Common Stock	Stock Options (Right to Buy)	Disposition	2011-11-01	2,500	$0.00	2,500	$48.74

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,950		2012-02-27	No	4	M	Direct
7,500		2012-02-22	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,768	Indirect	SDCP

Footnotes

The options vested in three installments on April 17, 2003, February 27, 2004 and February 27, 2005.
The options vested in three annual installments on February 22, 2006, February 22, 2007 and February 22, 2008.
This exercise and sale reported were effected pursuant to Rule 10b-5-1 sales plan adopted by the reporting person on February 7, 2011.
This transaction was executed in multiple trades at prices ranging from $54.78 to $54.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $54.55 to $54.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This amount also includes exempt purchases made under the Company's stock purchase plan since the date of the last filing on Form 4.
These underlying shares were acquired on a periodic basis by the trustee of the Company's Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a recent date. The number of shares is based on the account balance of the Company stock fund under the plan (which includes some money market instruments), divided by the market price of the Company's stock as of that date.